Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
Shattuck Labs, Inc. (STTK) to present corporate update at 42nd Annual J.P. Morgan Healthcare Conference
01/04/2024 - 04:05 PM
AUSTIN, TX and DURHAM, NC, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will present a corporate update and participate in one-on-one meetings at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8-11, 2024.
Presentation Details
A live webcast of the presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.
About Shattuck Labs, Inc. www.ShattuckLabs.com .
Investor & Media Contact: InvestorRelations@shattucklabs.com
What is the name of the company presenting at the 42nd Annual J.P. Morgan Healthcare Conference?
Shattuck Labs, Inc. (STTK)
What is the date of the presentation at the conference?
Thursday, January 11, 2024
Who will be the presenter at the conference?
Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Where will the conference be held?
Westin St. Francis, San Francisco, CA
Will the presentation be available for viewing online?
Yes, a live webcast will be available on the Events & Presentations section of the Company’s website.
STTK Rankings
#4347 Ranked by Stock Gains
STTK Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology
About STTK
shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. compounds derived from shattuck’s proprietary agonist redirected checkpoint, arc®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. the company’s lead wholly owned program, sl-172154 (sirpα-fc-cd40l), which is designed to block the cd47 immune checkpoint and simultaneously agonize the cd40 pathway, is being evaluated in a phase 1 trial. a second compound, sl-279252 (pd1-fc-ox40l), is being evaluated in a phase 1 trial in collaboration with takeda pharmaceuticals. additionally, the company is advancing a proprietary gamma delta t cell engager, gadlen™, platform, which is designed to bridge gamma delta t cells to tumor antigens for the treatment of patients with cancer. shattuck has offices in both austin, tex
